Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Role of glycol chitosan-incorporated ursolic acid nanoparticles in the treatment of osteosarcoma

Xing-Lin Zhang^1,2, Xing Lu², Wei Geng³, Gao-Wei Qu², Zhi-Yong Zhou², Lian-Hong Jiang⁴, Yun-Xiang Li², Xu Chen², Lin-Nie .⁵

¹Department of Orthopedics, Qilu Hospital of Shandong University, Jinan 250012; ²Department of Orthopedics, Yantaishan hospital, Yantai, Shandong, 264001; ³Department of Spine Surgery, Liaocheng People's Hospital, Liaocheng, Shandong Province, 252000; ⁴Department of Radiology, Yantaishan hospital, Yantai, Shandong, 264001; ⁵Department of Spine Surgery, Qilu Hospital of Shandong University, Jinan 250012, China.

For correspondence:- Lin-Nie . Email: mdnielin14@gmail.com Tel:+8653182169114

Received: 19 January 2015 Accepted: 8 August 2015 Published: 29 September 2015

Citation: Zhang X, Lu X, Geng W, Qu G, Zhou Z, Jiang L, et al. Role of glycol chitosan-incorporated ursolic acid nanoparticles in the treatment of osteosarcoma. Trop J Pharm Res 2015; 14(9):1581-1488 doi: 10.4314/tjpr.v14i9.6

© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of ursolic acid (UA)-incorporated glycol chitosan (GC) nanoparticles on inhibition of human osteosarcoma.

Methods: U2OS and Saos-2 osteosarcoma cells were transfected with ursolic acid (UA) incorporated glycol chitosan (GC) nanoparticles. Ultraviolet (UV) spectrophotometry was used to measure drug contents in nanoparticles at 365 nm with empty GC vehicles as blank. Bicinchoninic acid assay (BCA) method was employed to determine protein concentration. Identification of apoptosis and necrosis in osteosarcoma cells was performed by propidium iodide and FITC-annexin V reagents, respectively. FAC Scan flow cytometry was used to analyse apoptotic cells.

Results: Among the range of UA concentrations tested, the minimum effective concentration was 10 µM with half inhibitory concentration IC₅₀ of 25 µM. In U2OS cells, treatment with 10 and 25 µM UA-induced apoptosis in 5.89 ± 3.90 and 60.54 ± 5.40 % cells, respectively, compared to 2.05 ± 1.01 % cells for control. In Saos-2 cells, exposure to 10 and 25 µM UA induced apoptosis in 9.86 ± 8.89 and 47.54 ± 14.5 % cells, respectively, compared to 1.79 ± 0.23 % for control cells. Western blot analysis revealed translocation of Bax and Bcl-2 proteins from mitochondria to cell cytosol. Increase in UA concentration from 10 µM to 25 µM led to increase in the proportion of cells in G0/G1 phase and decrease in the number of cells in S and G2/M phases. These results confirm that UA transfection arrests cell cycle in G0/G1 phase in human osteosarcoma cell lines.

Conclusion: UA transfection resulted in the inhibition of cell proliferation, Ezh2 expression inhibition, and apoptosis via mitochondrial pathway due to decrease in membrane potential and release of cytochrome C, as well as cell cycle arrest in G0/G1 phase.

Keywords: Osteosarcoma, Cell cycle arrest, Palliation, Glycol chitosan, Ursolic acid